Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 6, 2003, Pages 506-516

  Dervieux, Thierry ^a   Hancock, Michael L ^a   Pui, Ching Hon ^a   Rivera, Gaston K ^a   Sandlund, John T ^a   Ribeiro, Raul C ^a   Boyett, James ^a   Evans, William E ^a   Relling, Mary V ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; HYPOXANTHINE; MERCAPTOPURINE; METHOTREXATE; THIOGUANOSINE; ANTINEOPLASTIC ANTIMETABOLITE; NUCLEOSIDE; TIOGUANINE; XANTHINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; B LYMPHOBLAST; CELL LEVEL; CELLULAR DISTRIBUTION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; INFANT; LEUKOCYTE COUNT; LOW DRUG DOSE; LYMPHOBLAST; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL; RANDOMIZATION; ACUTE LYMPHOCYTIC LEUKEMIA; BLOOD; BONE MARROW CELL; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

6-MERCAPTOPURINE; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW CELLS; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYPOXANTHINE; INJECTIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKOCYTE COUNT; METHOTREXATE; NUCLEOSIDES; THIOGUANINE; XANTHINES;

EID: 0037871834     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00063-8     Document Type: Article

References (35)

1. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998;339:605-15.
2. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 1985;82:4881-5.
3. Moran RG. Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol 1999;26(2 Suppl 6):24-32.
4. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001;61: 5810-6.
5. Bokkerink JP, Bakker MA, Hulscher TW, De Abreu RR, Schretlen ED, van Laarhoven JP, et al. Sequence-, time-and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts. Biochem Pharmacol 1986;35:3549-55.
6. Armstrong RD, Vera R, Snyder P, Cadman E. Enhancement of 6-thioguanine cytotoxic activity with methotrexate. Biochem Biophys Res Commun 1982;109:595-601.
7. Giverhaug T, Fuskevaag OM, Aarbakke J. Methotrexate increases red blood cell concentrations of 6-methylmercaptopurine ribonucleotide in rats in vivo. Cancer Chemother Pharmacol 1997;40:367-70.
8. Giverhaug T, Loennechen T, Aarbakke J. Increased concentrations of methylated 6-mercaptopurine metabolites and 6-thioguanine nucleotides in human leukemic cells in vitro by methotrexate. Biochem Pharmacol 1998;55: 1641-6.
9. Tan CT, Wollner N, Trippelt T, Goker E, Tong WP, Kheradpour A, et al. Pharmacologic-guided trial of sequential methotrexate and thioguanine in children with advanced malignancies. J Clin Oncol 1994;12:1955-62.
10. Camitta B, Mahoney D, Leventhal B, Lauer SJ, Shuster JJ, Adair S, et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1994;12:1383-9.
11. Mahoney DH Jr, Camitta BM, Leventhal BG, Shuster JJ, Civin CJ, Ganick DJ, et al. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Cancer 1995;75:2623-31.
12. Mahoney DH Jr, Shuster J, Nitschke R, Lauer SJ, Winick N, Steuber CP, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology group phase III trial. J Clin Oncol 1998;16:246-54.
13. Dervieux T, Hancock M, Pui C-H, Evans WE, Relling MV. Effect of methotrexate polyglutamates on thioguanine nucleotides concentrations during continuation therapy of acute lymphoblastic leukemia. Leukemia 2002;16: 209-12.
14. Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer S, Steuber CP, Camitta B. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 2000;18:1285-94.
15. Dervieux T, Brenner T, Hon YY, Zhou Y, Hancock ML, Sandlund JT, et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 2002;100: 1240-7.
16. Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 2000;14:2257-66.
17. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002;16:1099-111.
18. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97: 1211-8.
19. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499-505.
20. Pui CH, Relling MV, Lascombes F, Harrison PL, Struxiano A, Mondesir JM, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997;11:1813-6.
21. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996;97:73-80.
22. Su Y, Hon YY, Chu Y, Van de Poll ME, Relling MV. Assay of 6-mercaptopurine and its metabolites in patient plasma by high-performance liquid chromatography with diode-array detection. J Chromatogr B Biomed Sci Appl 1999;732:459-68.
23. Dervieux T, Chu YQ, Su E, Pui C-H, Evans WE, Relling MV. HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblast following mercaptopurine. Clin Chem 2002;48:161-8.
24. Wung WE, Howell SB. Simultaneous liquid chromatography of 5-fluorouracil, uridine, hypoxanthine, xanthine, uric acid, allopurinol, and oxipurinol in plasma. Clin Chem 1980;26:1704-8.
25. Boulieu R, Bory C, Baltassat P, Gonnet C. Hypoxanthine and xanthine levels determined by high-performance liquid chromatography in plasma, erythrocyte, and urine samples from healthy subjects: the problem of hypoxanthine level evolution as a function of time. Anal Biochem 1983;129:398-404.
26. Proc-StatXact for SAS users: statistical software for exact nonparametric inference. Cambridge (MA): Cytel Corp; 2001.
27. Hashimoto H, Kubota M, Shimizu T, Takimoto T, Kitoh T, Akiyama Y, et al. Biochemical basis of the prevention of 6-thiopurine toxicity by the nucleobases, hypoxanthine and adenine. Leuk Res 1990;14:1061-6.
28. Zimm S, Johnson GE, Poplack DG. Modulation of thiopurine cytotoxicity in the HL-60 cell line by physiological concentrations of hypoxanthine. Cancer Res 1986; 46:6286-9.
29. Lewis AS, Murphy L, McCalla C, Fleary M, Purcell S. Inhibition of mammalian xanthine oxidase by folate compounds and amethopterin. J Biol Chem 1984;259:12-5.
30. Balis FM, Holcenberg JS, Zimm S, Tubergen D, Collins JM, Murphy RF, et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 1987;41:384-7.
31. Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood 1998;92:3569-77.
32. Innocenti F, Danesi R, Di Paolo A, Loru B, Favre C, Nardi M, et al. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother Pharmacol 1996;37:409-14.
33. Krenitsky TA, Papaioannou R, Elion GB. Human hypoxanthine phosphoribosyltransferase. I. Purification, properties, and specificity. J Biol Chem 1969;244:1263-70.
34. Frei E III, Freireich EJ, Gehan E, Pinkel D, Holland JF. Studies of sequential and combination antimetabolite therapy in acute lymphoblastic leukemia: 6-mercaptopurine and methotrexate. Blood 1961;18:431-53.
35. Aur RJ, Simone JV, Verzosa MS, Hustu HO, Barker LF, Pinkel DP, et al. Childhood acute lymphocytic leukemia: study VIII. Cancer 1978;42:2123-34.